Abstract
Clenbuterol is a beta 2-sympathomimetic bronchodilator. In a double-blind cross-over trial in 19 asthmatic patients with reversible airways obstruction, oral administration of both clenbuterol (40 microgram) and salbutamol (4 mg) caused significantly greater increased in peak expiratory flow rate (PEFR) than placebo, that of clenbuterol lasting longer. The patients' subjective assessment also suggested the relief of their symptoms by the active drugs. Side-effects were minimal.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Kamburoff P. L., Prime F. J., Schmidt O. P. The bronchodilator effect of NAB 365. Br J Clin Pharmacol. 1977 Feb;4(1):67–71. doi: 10.1111/j.1365-2125.1977.tb00669.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lal S., Dash C. H., Gribben M. D. An economical method of comparing inhaled bronchodilators in reversible diffuse airways obstruction. With special reference to a beta-2 stimulant--salmefamol. Thorax. 1974 May;29(3):317–322. doi: 10.1136/thx.29.3.317. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Zimmer A. Einmalapplikation, Mehrfachapplikation und Metabolitenmuster von Clenbuterol beim Menschen. Arzneimittelforschung. 1976;26(7A):1446–1450. [PubMed] [Google Scholar]